GlassScriptPhysician profile
Marco A Vargas
NPI 1760582647
$1,178.81
in general payments reported to CMS, 2019-2025
15 companies · $28.87 in 2025
The $28.87 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $445 · 2020: $132 · 2021: $426 · 2022: $147 · 2025: $28.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $28.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $28.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $424.09 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $164.73 | 2019 | |
| Bone Support INC. | $158.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $120.00 | 2019 | |
| Stryker Corporation | $82.02 | 2019-2020 | |
| Organogenesis INC. | $63.00 | 2021 | |
| Nabriva Therapeutics, Plc | $28.44 | 2020-2021 | |
| Celularity INC. | $28.00 | 2019 | |
| Melinta Therapeutics, LLC | $22.45 | 2019 | |
| Grt US Holding, INC. | $21.09 | 2020 | |
| Zimmer Biomet Holdings, INC. | $21.04 | 2019 | |
| Paratek Pharmaceuticals, INC. | $17.08 | 2021 | |
| Mimedx Group, INC. | $15.34 | 2025 | |
| Biotissue Holdings INC. | $13.53 | 2025 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$1,537,616.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marco Vargas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.